To assess the effect of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients who have failed to 1st-line chemotherapy.
This is a open-label, phase II, umbrella study enrolling advanced biliary tract cancer patients who have failed to 1st-line chemotherapy. Patients will be enrolled to AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination cohorts. Based on the new emerging therapies, cohorts can be added into existing protocol.
One cycle consists of 4weeks. Response evaluation will be done every 8 weeks (every 2 cycles) of treatment
| Condition | Cholangiocarcinoma, Biliary neoplasm, cancer of the bile duct, Bile duct carcinoma, Chemotherapy Effect, Biliary Tract Cancer, Urothelial Tract Cancer |
|---|---|
| Treatment | durvalumab, olaparib, AZD6738 |
| Clinical Study Identifier | NCT04298021 |
| Sponsor | Seoul National University Hospital |
| Last Modified on | 25 May 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.